PARIS – Dechert LLP assisted Vexim in connection with a tender offer filed today by Stryker Corporation.
Stryker Corporation acquired on October 24, 2017 a majority stake in Vexim through an off-market sale transaction with Truffle Capital, Bpifrance, Kreaxi and managers of Vexim. A simplified tender offer was then filed by Stryker Corporation before the French Financial Markets Authority (Autorité des Marchés Financiers) for the acquisition of all remaining Vexim securities. This tender offer is expected to close at the beginning of December 2017.
Vexim is a French medtech company specializing in spine trauma. It was established in 2006 and is listed on EURONEXT Growth. Stryker Corporation is one of the world's leading medical technology companies, whose products are sold in over 100 countries.
The value of Vexim under this transaction is 183m€.
The Paris-based team advising Vexim was led by national partner Charles Cardon, with support from associates Quentin Durand and Vianney Toulouse (corporate).
Read the press release in French (PDF): Offre publique d’acquisition de Stryker sur Vexim
About Dechert
Dechert is a global law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients' most important matters. Nothing stands in the way of giving clients the best of the firm's entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.